LOS ANGELES, CA– In a groundbreaking achievement set to reshape the future of transplant medicine, Dr. Inderbir S. Gill has led the world’s first successful bladder transplant in a human being. The ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

Risk factors are things that raise your chances of getting a disease. There are different types of risk factors such as genetic, biological, lifestyle and exposure. For each person, a mix of these ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment ...

(RTTNews) - AstraZeneca (AZN), Friday announced positive Phase III results from its POTOMAC trial, showing that adding one year of treatment with Imfinzi; durvalumab to standard BCG therapy ...

Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone WILMINGTON, Del.-- ...

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial Adding one year of IMFINZI treatment ...

Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at 12 weeks Good tolerability with no systemic side effects First DNA medicine to selectively target, at the local level ...

Hi, I’m Luke! I’m passionate about buying, selling, breeding, and keeping goldfish — and I’ve built a space to share everything I’ve learned along the way. Whether you’re new to goldfish keeping or a ...

After decades of limited options, a groundbreaking FDA-approved treatment is opening new doors for people with certain types of bladder cancer. Supported by Johnson & Johnson Bill is a real patient ...